natgillin/translations-raw huggingface dataset:
• Acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,
• akutno zmedenost, krče (epilepsijo), komo, kombinacijo zvišane telesne temperature, hitrega dihanja, znojenja;
Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).
Zdravilo Aripiprazol Zentiva je indicirano za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I ter za preprečevanje novih maničnih epizod pri odraslih bolnikih, ki so doživljali pretežno manične epizode, ki so bile odzivne na zdravljenje z aripiprazolom (glejte poglavje 5.1).
The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3%), somnolence (27.3%), headache (23.2%), and nausea (14.1%).
Pri bolnikih, ki so prejemali odmerek 30 mg, so bili najpogostejši neželeni učinki ektrapiramidne motnje (28,3 %), zaspanost (27,3 %), glavobol (23,2 %) in navzea (14,1 %).
Aripiprazole Zentiva is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling “high”, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Zdravilo Aripiprazol Zentiva uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35 for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.
Po jemanju aripiprazola je bilo 8. teden vidno izboljšanje s spremembo od izhodiščne vrednosti rezultata TTS-YGTSS za 13,35 točk pri skupini z nizkim odmerkom (5 ali 10 mg) in za 16,94 točk pri skupini z visokim odmerkom (10 ali 20 mg) v primerjavi z izboljšanjem za 7,09 točk pri skupini, ki je prejemala placebo.
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
Populacijska farmakokinetična analiza ni pokazala klinično pomembnih učinkov kajenja na farmakokinetiko aripiprazola.
Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline.
Bolniki so bili stari od 6 do 18 let, njihov povprečni izhodiščni rezultat na lestvici TTS-YGTSS pa je bil 29.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (see section 5.1).
V kliničnih preskušanjih in v obdobju trženja aripiprazola so za odobrene indikacije opazili povečanje in zmanjšanje serumskega prolaktina v primerjavi z izhodiščnimi vrednostmi (poglavje 5.1).
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when aripiprazole (30 mg) was administered alone.
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4, in peroralnega aripiprazola pri bolnikih s shizofrenijo in shizoafektivno motnjo je bila geometrična sredina Cmax za 68 % nižja, AUC pa za 73 % nižja kot po uporabi samega aripiprazola (30 mg).
The safety and efficacy of aripiprazole in children and adolescents 6 to 18 years of age have not yet been established.
Varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, starih od 6 do 18 let, še ni bili dokazani.
Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Aripiprazol ima blag do zmeren vpliv na sposobnost vožnje in upravljanje strojev zaradi morebitnega vpliva na živčni sistem in vid, kot je sedacija, somnolenca, sinkopa, zamegljen vid in diplopija (glejte poglavje 4.8).
Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5% of aripiprazole treated patients as compared to 2.0% of patients who received placebo.
Zvišanje CPK (kreatin-fosfokinaze), ki je praviloma prehodno in asimptomatsko, je bilo zabeleženo pri 3,5 % bolnikov, zdravljenih z aripiprazolom, in pri 2,0 % bolnikov, ki so dobivali placebo.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)
Žilne bolezni ortostatska hipotenzija venska trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
What you need to know before you take Aripiprazole Zentiva
Kaj morate vedeti, preden boste vzeli zdravilo Aripiprazol Zentiva
In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34% in aripiprazole group and 57% in placebo.
V 26-tedenskem, s placebom nadzorovanem preskušanju stabiliziranih odraslih bolnikov s kronično shizofrenijo je aripiprazol značilno bolj zmanjšal delež recidivov: v skupini, ki je dobivala aripiprazol, jih je bilo 34 %, v tisti, ki je dobivala placebo, pa 57 %.
In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63% and 37%, respectively.
V kliničnem preskušanju pri zdravih preiskovancih je močan zaviralec CYP3A4 (ketokonazol) zvečal AUC aripiprazola za 63 % in Cmax za 37 %.
• feeling tired.
• bruhanje, • utrujenost.
Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.
Pri odmerkih, višjih od 10 mg/dan, večje učinkovitosti niso dokazali, vendar pa posameznim bolnikom lahko koristi tudi zdravljenje z večjim odmerkom.
• Medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)
• zdravila proti motnjam srčnega ritma (kot so kinidin, amiodaron, flekainid),
The recommended starting dose for Aripiprazole Zentiva is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
Priporočeni začetni odmerek zdravila Aripiprazol Zentiva je 15 mg enkrat na dan ne glede na obroke hrane, in sicer kot samostojno zdravilo ali v sklopu kombiniranega zdravljenja (glejte poglavje 5.1).
The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1%, 30 mg, 28.8%, placebo, 1.7%,); and akathisia (incidences were 10 mg, 12.1%, 30 mg, 20.3%, placebo, 1.7%).
Naslednji neželeni učinki bi lahko bili povezani z velikostjo odmerka: ekstrapiramidne motnje (pri uporabi 10 mg odmerka je bila pojavnost 9,1 %, pri uporabi 30 mg odmerka 28,8 %, pri uporabi placeba pa 1,7 %) in akatizija (pri uporabi 10 mg odmerka je bila pojavnost 12,1 %, pri uporabi 30 mg odmerka 20,3 %, pri uporabi placeba pa 1,7 %).
• Antifungal medicines (such as ketoconazole, itraconazole)
• zdravila proti glivicam (kot sta ketokonazol, itrakonazol),
The recommended starting dose for Aripiprazole Zentiva is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
Priporočeni začetni odmerek zdravila Aripiprazol Zentiva je 10 ali 15 mg/dan, vzdrževalni odmerek pa 15 mg/dan, uporabljen enkrat na dan ne glede na obroke.
If you are taking Aripiprazole Zentiva, your doctor will discuss with you whether you should breast feed considering the benefit to you of your therapy and the benefit to your baby of breast feeding.
Če prejemate zdravilo Aripiprazol Zentiva, vam bo zdravnik pomagal pri odločitvi glede dojenja z upoštevanjem prednosti dojenja za otroka in prednosti zdravljenja za vas.
The following symptoms may occur in newborn babies, of mothers that have used Aripiprazole Zentiva in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Aripiprazol Zentiva, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
• Certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz,
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Zentiva.
Zdravilo tudi preprečuje ponovitve pri odraslih bolnikih, ki so se odzvali na zdravljenje z zdravilom Aripiprazol
Each tablet contains 5 mg/10 mg/15 mg/30 mg of aripiprazole.
Ena tableta vsebuje 5 mg/10 mg/15 mg/30 mg aripiprazola.
Irritability associated with autistic disorder in paediatric patients (see section 4.2) Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 - 15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week openlabel trial.
Razdražljivost, povezana z avtistično motnjo, pri pediatričnih bolnikih (glejte poglavje 4.2) Uporabo aripiprazola so pri bolnikih, starih od 6 do 17 let, raziskovali v dveh 8-tedenskih, s placebom nadzorovanih preskušanjih [v enem z uporabo fleksibilnega odmerka (od 2 do 15 mg/dan), v drugem pa z uporabo fiksnega odmerka (5, 10 ali 15 mg/dan)] in v enem 52-tedenskem odprtem preskušanju.
Potential for other medicinal products to affect aripiprazole A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant.
Zaviralec izločanja želodčne kisline, antagonist H2 famotidin, zmanjša hitrost absorpcije aripiprazola, vendar ta učinek ne velja za klinično pomembnega.
Aripiprazole Zentiva tablets contain lactose.
Tablete Aripiprazol Zentiva vsebujejo laktozo.
The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly
Profil varnosti v dolgotrajnem dvojnoslepem, s placebom nadzorovanem kliničnem preskušanju je bil prav tako podoben, razen pri naslednjih reakcijah, o katerih so poročali pogosteje pri pediatričnih bolnikih, ki so jemali placebo: pogosto so navajali zmanjšanje telesne mase, zvišano vrednost inzulina v krvi, aritmijo in levkopenijo (≥ 1/100, < 1/10).
• Anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)
• antikonvulzive, ki se uporabljajo za zdravljenje epilepsije (kot so karbamazepin, fenitoin,
- If you have any further questions, ask your doctor or pharmacist.
− Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
• Other anti-depressants (such as venlafaxine and tryptophan) used in major depression
• druge antidepresive (kot sta venlafaksin in triptofan) uporabljamo za veliko depresijo,
Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69% and 71% lower, respectively, than those following treatment with aripiprazole alone.
Podobno je bila po sočasni uporabi karbamazepina geometrična sredina Cmax dehidroaripiprazola za 69 % nižja, njegova AUC pa za 71 % nižja kot po zdravljenju s samim aripiprazolom.
Aripiprazole Zentiva is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila Aripiprazol Zentiva pri bolnikih s shizofrenijo, mlajših od 15 let, ni priporočljiva (glejte poglavji 4.8 in 5.1).
• slower heart beat,
• počasnejše bitje srca,
In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 - 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.
V 6-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 302 mladostnika (13-17 let) s shizofrenijo s pozitivnimi in negativnimi simptomi, je bil aripiprazol povezan s statistično značilno večjim izboljšanjem psihotičnih simptomov v primerjavi s placebom.
Recurrence prevention of manic episodes in Bipolar I Disorder For preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose.
Preprečevanje ponovitev maničnih epizod pri bipolarni motnji I Za preprečevanje ponovitev maničnih epizod pri bolnikih, ki so se zdravili z aripiprazolom samostojno ali v sklopu kombiniranega zdravljenja, se zdravljenje nadaljuje z istim odmerkom.
Pathological gambling and other impulse control disorders Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole.
Pri bolnikih se lahko poveča impulzivnost, zlasti želja po igrah na srečo, med jemanjem aripiprazola pa teh niso več sposobni nadzorovati.
• Antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine,
• antidepresive ali pripravke rastlinskega izvora proti depresiji in tesnobnosti (kot so fluoksetin,
OPA/Alu/PVC/Alu foil blisters (Alu-Alu blister), carton box.
6.5 Vrsta ovojnine in vsebina OPA/Alu/PVC/Alu pretisni omoti (Alu-Alu pretisni omot), škatla.
Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)
Bolezni imunskega sistema alergijska reakcija (npr. anafilaksijska reakcija, angioedem, vključno z oteklino jezika, edem jezika, edem obraza, srbenje ali urtikarija)
Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand,
S pozitronsko emisijsko tomografijo so pokazali, da je 2-tedenska uporaba odmerkov od 0,5 do 30 mg aripiprazola enkrat na dan pri zdravih preiskovancih povzročila od odmerka odvisno zmanjšanje vezave 11C-rakloprida, liganda receptorjev D2/D3, v nucleusu caudatusu in putamnu.
• Tricyclic's (such as clomipramine and amitriptyline) used for depressive illness
• triciklične antidepresive (kot sta klomipramin in amitriptilin) uporabljamo za depresijo,
The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4%, compared with 0.02% for patients treated with placebo.
Pojavnost hipoprolaktinemije ali znižane ravni prolaktina v serumu pri bolnikih, zdravljenih z aripiprazolom, je bila 0,4 % v primerjavi s skupino s placebom (0,02 %).
When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section
Bolnik nato začne jemati priporočeni dnevni odmerek 10 mg. Odmerek se po potrebi lahko nato še nadalje povečuje po 5 mg, vendar pa ne sme preseči največjega dnevnega odmerka 30 mg (glejte poglavje 5.1).
Suicide attempt, suicidal ideation and completed suicide (see section 4.4) Pathological gambling Impulse-control disorders Binge eating
Psihiatrične motnje nespečnost anksioznost nemir depresija hiperseksualnost poskus samomora, misli na samomor in samomor (glejte poglavje 4.4) patološko hazardiranje motnje nadzora impulzov kompulzivno prenajedanje kompulzivno nakupovanje poriomanija agresija agitacija živčnost
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older The recommended dose for Aripiprazole Zentiva is 10 mg/day administered on a once-a-day schedule without regard to meals.
Manične epizode pri bipolarni motnji I pri mladostnikih, starih 13 let in več Priporočeni odmerek zdravila Aripiprazol Zentiva je 10 mg enkrat na dan ne glede na obrok hrane.
In schizophrenia patients the incidence of akathisia was 6.2% with aripiprazole and 3.0% with placebo.
Pri bolnikih s shizofrenijo je bila pojavnost akatizije pri uporabi aripiprazola 6,2 %, pri uporabi placeba pa 3,0 %.
Additional side effects in children and adolescents Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (may affect more than 1 in 10 people) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (may affect up to 1 in 10 people).
Neželeni učinki pri mladostnikih, starih 13 let in starejših, so bili po pogostnosti in vrsti podobni neželenim učinkom pri odraslih, z izjemo naslednjih: zaspanost, nenadzorovani trzaji ali nehotni gibi, nemirnost in utrujenost, ki so bili zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov), ter bolečina v zgornjem predelu trebuha, suha usta, hiter srčni utrip, povečanje telesne mase, povečan apetit, trzanje mišic, nenadzorovano gibanje udov in omotica, še posebej pri vstajanju iz ležečega ali sedečega položaja, ki so bili pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov).
Pack size: 14, 28, 49, 56, or 98 tablets
Velikost pakiranja: 14, 28, 49, 56 ali 98 tablet.
Neuroleptic Malignant Syndrome (NMS) Grand mal convulsion Serotonin syndrome Speech disorder
generalizirana konvulzija serotoninski sindrom motnje govora
The AUC and Cmax of dehydro-aripiprazole increased by 77% and 43%, respectively.
AUC dehidroaripiprazola se je zvečala za 77 %, njegova Cmax pa za 43 %.
Aripiprazole Zentiva orodispersible tablets contain lactose.
Orodisperzibilne tablete Aripiprazol Zentiva vsebujejo laktozo.
Aripiprazole Zentiva 10 mg, 30 mg tablets: The score line is not intended for breaking the tablet.
Aripiprazol Zentiva 10 mg, 30 mg tablete: Zareza ni namenjena delitvi tablete.
Manic episodes in Bipolar I Disorder in children and adolescents Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10 - 17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline.
Manične epizode pri bipolarni motnji I pri otrocih in mladostnikih Uporabo aripiprazola so raziskovali v 30-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 296 otrok in mladostnikov (10-17 let), ki so ustrezali kriterijem DSM-IV za bipolarno motnjo I z maničnimi ali mešanimi epizodami s psihotičnimi lastnostmi ali brez njih, in so imeli v izhodišču oceno ≥ 20 po lestvici Y-MRS. Izmed bolnikov, ki so bili vključeni v primarno analizo učinkovitosti, je imelo 139 bolnikov sočasno tudi diagnozo motnje pomanjkanja pozornosti (ADHD
Method of administration Aripiprazole Zentiva is for oral use.
Zdravilo Aripiprazol Zentiva je namenjeno za peroralno uporabo.
Increased Alanine Aminotransferase (ALT)
zvišana aktivnost aspartat aminotransferaze (AST)
The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32% and 47%, respectively.
AUC aktivnega presnovka dehidroaripiprazola se je zmanjšala za 32 %, njegova Cmax pa za 47 %.
In another 12-week trial, the incidence of EPS was 26.6% for patients treated with aripiprazole and 17.6% for those treated with lithium.
V drugem 12-tedenskem preskušanju je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 26,6 %, pri bolnikih, ki so se zdravili z litijem pa 17,6 %.
Schizophrenia in adolescents aged 15 years and older In a short-term placebo-controlled clinical trial involving 302 adolescents (13 - 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo): Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, < 1/10).
V kratkotrajnem, s placebom nadzorovanem kliničnem preskušanju, ki je vključevalo 302 mladostnika (13-17 let) s shizofrenijo, so bili neželeni učinki po pogostnosti in vrsti podobni kot pri odraslih, z izjemo naslednjih neželenih učinkov, ki so bili pri mladostnikih, ki so prejemali aripiprazol, pogostejši kot pri odraslih, ki so prejemali aripiprazol (in pogostejši kot pri placebu): Somnolenca/sedacija in ekstrapiramidne motnje so bili zelo pogosti (≥ 1/10), suha usta, povečan apetit in ortostatska hipotenzija pa pogosti (≥ 1/100, < 1/10) neželeni učinki.
Aripiprazole Zentiva 10 mg, 30 mg orodispersible tablets: The score line is not intended for breaking the tablet.
Aripiprazol Zentiva 10 mg, 30 mg orodisperzibilne tablete: Zareza ni namenjena delitvi tablete.
Manic episodes in Bipolar I Disorder - in a 12-week controlled trial, the incidence of EPS was 23.5% for aripiprazole-treated patients and 53.3% for haloperidol-treated patients.
Manične epizode pri bipolarni motnji I - v 12-tedenskem nadzorovanem preskušanju je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 23,5 %, pri bolnikih, ki so se zdravili s haloperidolom pa 53,3 %.
Schizophrenia - in a long term 52-week controlled trial, aripiprazole-treated patients had an overalllower incidence (25.8%) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3%).
Shizofrenija - v dolgoročnem 52-tedenskem nadzorovanem preskušanju je bila celotna incidenca EPS (vključno s parkinsonizmom, akatizijo, distonijo in diskinezijo) manjša (25,8 %) pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali haloperidol (57,3 %).
The active substance is aripiprazole.
Učinkovina je aripiprazol.
The other ingredients are lactose monohydrate, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, silica colloidal anhydrous, croscarmellose sodium, acesulfame potassium, mango flavour, magnesium stearate.
Druge sestavine zdravila so laktoza monohidrat, mikrokristalna celuloza, krospovidon, hidroksipropilceluloza, brezvodni koloidni silicijev dioksid, premrežen natrijev karmelozat, kalcijev acesulfamat, aroma manga, magnezijev stearat.
How to take Aripiprazole Zentiva
Kako jemati zdravilo Aripiprazol Zentiva
Overall, 1.3% of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6% of placebo-treated patients in these trials.
V celoti so v teh preskušanjih cerebrovaskularne neželene učinke zabeležili pri 1,3 % bolnikov, zdravljenih z aripiprazolom, in pri 0,6 % bolnikov, ki so dobivali placebo.
Excipient with known effect: each orodispersible tablet contains 55.5 mg of lactose (as monohydrate) and 1.97 mg of sodium.
Pomožna snov z znanim učinkom: ena orodisperzibilna tableta vsebuje 55,5 mg laktoze (v obliki monohidrata) in 1,97 mg natrija.
In the pooled trials, the incidence of low serum prolactin levels in females (< 3 ng/ml) and males (< 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7%) and 258/298 (86.6%), respectively.
Podatki združenih preskušanj kažejo, da je bila pri zdravljenju z aripiprazolom pogostnost nizkih vrednosti prolaktina v serumu pri deklicah (< 3 ng/ml) 58,7 % (27/46), pri dečkih (< 2 ng/ml) pa 86,6 % (258/298).
Pack size: 14, 28 or 49 orodispersible tablets
Velikost pakiranja: 14, 28 ali 49 orodisperzibilnih tablet.